

## References

### I-221

1. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicenter, open-label, phase 3 study. *The Lancet*. 2019;394(10214):2096-2107.
2. Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Blood*. 2019;134(2):123-133.
3. Richardson PG, Attal M, Campana F, et al. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA phase III study design. *Future Oncology*. 2018;14(11):1035-1047.
4. National Comprehensive Cancer Network (NCCN). Isatuximab-irfc. NCCN Drugs and Biologics Compendium®. 2023.
5. Sarclisa (isatuximab-irfc) injection, for intravenous use [package insert]. Sanofi-Aventis U.S., LLC. Bridgewater, NJ. Revised 07/2022.
6. Micromedex®Solutions Compendia. 2023. Isatuximab-irfc.
7. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2021;397(10292):2361-2371.
8. Clinical Pharmacology™ 2023. Tampa FL: Gold Standard, Inc. Generic Isatuximab.
9. Isatuximab-irfc. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 12, 2021.